CANY
MCRB icon

Caxton Associates (New York)’s Seres Therapeutics MCRB Stock Holding History

Caxton Associates (New York)’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,108
Closed -$271K – 552
2022
Q3 		$271K Sell
2,108
-1,854
-47% -$190K 0.04% 341
2022
Q2 		$272K Buy
+3,962
New +$341K 0.03% 406

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Caxton Associates (New York)'s MCRB Position: Q4 2022 in Review

Caxton Associates (New York) sold out of Seres Therapeutics (MCRB) in Q4 2022, closing a stake of 2,108 shares — an estimated $271K sold.

Caxton Associates (New York) first reported a position in MCRB in Q2 2022 and held it in 2 quarters. The position peaked at $272K in Q2 2022. 123 funds tracked by Wall St. Rank hold MCRB as of Q4 2022.

  • Caxton Associates (New York) reported no remaining Seres Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 2,108 Seres Therapeutics shares in Q4 2022, an estimated $271K.
  • Caxton Associates (New York) first reported a position in Seres Therapeutics in Q2 2022 and held it in 2 quarters.
  • Caxton Associates (New York)'s Seres Therapeutics position peaked at $272K in Q2 2022.
  • 123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2022.

Based on Caxton Associates (New York)'s 13F filing for Q4 2022, filed 14 Feb 2023.